Evaxion Overview
- Year Founded
-
2008
- Status
-
Public
- Employees
-
46
- Stock Symbol
-
EVAX
- Share Price
-
$2.75
- (As of Friday Closing)
Evaxion General Information
Description
Evaxion AS is a clinical-stage TechBio company developing novel vaccines with its proprietary, clinically validated and scalable AI platform, AI-Immunology. The platform harnesses the power of artificial intelligence to decode the human immune system and develop novel vaccine candidates for cancer and infectious diseases for patients in the market. Evaxion has developed a clinical-stage oncology pipeline of novel personalised vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. The group is committed to transforming patients' lives by providing inventive and targeted treatment options.
Contact Information
Website
evaxion.aiCorporate Office
- Drive Neergaards Vej 5 F
- 2970 Hoersholm
- Denmark
Corporate Office
- Drive Neergaards Vej 5 F
- 2970 Hoersholm
- Denmark
Evaxion Stock Performance
As of 13-Nov-2026, Evaxion’s stock price is $2.75. Its current market cap is $25.3M with 9.2M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $2.75 | $2.77 | $2.65 - $6.92 | $25.3M | 9.2M | 240K | -$1.50 |
Evaxion Financials Summary
As of 30-Jun-2026, Evaxion has a trailing 12-month revenue of $7.49M.
|
In Thousands, USD |
TTM 30-Jun-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 25,855 | 39,783 | 4,959 | 25,987 |
| Revenue | 7,492 | 7,528 | 3,344 | 73 |
| EBITDA | (6,726) | (7,423) | (10,040) | (21,557) |
| Net Income | (8,659) | (7,707) | (10,567) | (22,125) |
| Total Assets | 19,380 | 28,408 | 12,485 | 12,889 |
| Total Debt | 7,105 | 7,504 | 10,101 | 10,870 |
Evaxion Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Evaxion Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Evaxion Comparisons
Industry
Financing
Details
Evaxion Competitors (10)
One of Evaxion’s 10 competitors is Numerion Labs, a Venture Capital-Backed company based in San Francisco, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Numerion Labs | Venture Capital-Backed | San Francisco, CA | ||||
| Genmab | Formerly VC-backed | Valby, Denmark | ||||
| Merck & Co. | Corporation | Rahway, NJ | ||||
| Lantern Pharma | Formerly VC-backed | Dallas, TX | ||||
| InSilico Medicine Cayman | Formerly VC-backed | Hong Kong, Hong Kong |
Evaxion Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Evaxion Patents
Evaxion Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026120145-A1 | Vaccine composition comprising herv derived epitopes and their use in treatment of aml | Pending | 05-Dec-2024 | ||
| AU-2025235873-A1 | Mhc ligand identification and related systems and methods | Pending | 15-Mar-2024 | ||
| WO-2025191132-A1 | Mhc ligand identification and related systems and methods | Pending | 15-Mar-2024 | ||
| WO-2025158034-A1 | Method for optimizing selection of an effective vaccine agent | Pending | 24-Jan-2024 | ||
| JP-2026532126-A | Immunogenic variant of human cytomegalovirus glycoprotein b | Pending | 12-Sep-2023 | C07K14/005 |
Evaxion Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Evaxion FAQs
-
When was Evaxion founded?
Evaxion was founded in 2008.
-
Where is Evaxion headquartered?
Evaxion is headquartered in Hoersholm, Denmark.
-
What is the size of Evaxion?
Evaxion has 46 total employees.
-
What industry is Evaxion in?
Evaxion’s primary industry is Biotechnology.
-
Is Evaxion a private or public company?
Evaxion is a Public company.
-
What is Evaxion’s stock symbol?
The ticker symbol for Evaxion is EVAX.
-
What is the current stock price of Evaxion?
As of 13-Nov-2026 the stock price of Evaxion is $2.75.
-
What is the current market cap of Evaxion?
The current market capitalization of Evaxion is $25.3M.
-
What is Evaxion’s current revenue?
The trailing twelve month revenue for Evaxion is $7.49M.
-
Who are Evaxion’s competitors?
Numerion Labs, Genmab, Merck & Co., Lantern Pharma, and InSilico Medicine Cayman are some of the 10 competitors of Evaxion.
-
What is Evaxion’s annual earnings per share (EPS)?
Evaxion’s EPS for 12 months was -$1.50.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
